Esperion Therapeutics Q2 Earnings Preview: EPS -$0.16, Revenue $63.05M

Esperion Therapeutics (ESPR) is set to announce Q2 earnings on August 5th. Analysts expect EPS of -$0.16 and a 14.6% revenue decline to $63.05 million YoY. The average analyst price target suggests a 306.02% potential upside. Esperion has consistently outperformed revenue expectations over the past year.

Esperion Therapeutics (ESPR), a biopharmaceutical company focused on treating patients with elevated low-density lipoprotein cholesterol (LDL-C), is set to announce its Q2 earnings results on August 5th. Analysts expect the company to report an earnings per share (EPS) of -$0.16 and a 14.6% year-over-year (YoY) decline in revenue to $63.05 million. Despite the anticipated loss, the average analyst price target suggests a potential 306.02% upside.

Historically, Esperion Therapeutics has consistently outperformed revenue expectations. Over the past year, the company has beaten revenue estimates 100% of the time [2]. However, the company has faced challenges with its EPS performance, missing estimates in the last three quarters. In Q1 2025, the company missed the EPS estimate by $0.06, resulting in a 10.72% drop in the share price the next day [1].

The current share price of Esperion Therapeutics is $1.4, down 25.87% over the last 52 weeks. The company's stock has been influenced by future projections rather than past performance. The average analyst rating on the shares is "buy," with a breakdown of 5 "strong buy" or "buy," 2 "hold," and 1 "sell" or "strong sell" [3].

Institutional investors have shown interest in Esperion Therapeutics. Large investors such as Nuveen LLC, Wasatch Advisors LP, and Bank of America Corp DE have increased their holdings in the company's stock [4]. Despite the recent downward trend, the company's pipeline of non-statin medicines, including NEXLETOL and NEXLIZET, holds promise for future growth.

Analysts expect Esperion Therapeutics to report a loss of 13 cents per share, with a 13.6% decrease in revenue. The company's ability to navigate these challenges and provide positive guidance for the next quarter will be closely watched by investors. The stock's performance will likely be heavily influenced by the company's earnings release and any forward-looking statements provided.

References:
[1] https://www.benzinga.com/insights/earnings/25/08/46841546/what-to-expect-from-esperion-therapeutics-earnings
[2] https://seekingalpha.com/news/4477419-esperion-therapeutics-q2-2025-earnings-preview
[3] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TT256:0-esperion-therapeutics-inc-expected-to-post-a-loss-of-13-cents-a-share-earnings-preview/
[4] https://www.marketbeat.com/instant-alerts/what-is-zacks-researchs-forecast-for-espr-q1-earnings-2025-07-30/